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n cancer, as in life, DNA doesn't have the last word. Although some gene mutations can predict response to certain targeted therapies, single-gene testing has limits.
"Most of biology and probably the large fraction of cancer biology doesn't occur at a chromosomal level," said NCI geneticist Ken Buetow, Ph.D., at the 2010 American Association for Cancer Research conference on molecular diagnostics. "It occurs at a network level." Many alterations in many genes interact to create the cancer phenotype, Buetow said, with the frequency of any single alteration "very rarely above single-digit percentages."
What's needed, according to Buetow and others, are diagnostic tests that can examine multiple points in these networks simultaneously and use the information to predict how likely a given treatment is to work. "Clearly, we have to move from looking at single molecules and even single pathways to looking at networks and how they interact if we're going to move forward," said Gordon Mills, M.D., Ph.D. , chair of the department of systems biology at the M. D. Anderson Cancer Center in Houston.
Such pathway and network diagnostic tests may be on the way. Some of the most advanced are designed to detect alterations in proteins, since proteins -especially phosphorylated signaling proteinsmore directly reveal the activation state of pathways and networks than do DNA sequence or gene expression. "We give you contextual understanding of the net result of all the physiological, of all the genetic change, and all the epigenetic change, and probably other control system changes," said David Parkinson, M.D., CEO of South San Francisco, Calif., biotech company Nodality, which is developing some of the new proteomic diagnostic tests. "That's the level at which drugs work or don't work."
The success of these methods will depend on the ability of companies to validate the tests ' effectiveness and reproducibility in clinical trials. For some, such trials are already under way.
Going With the Flow
By focusing on protein activation, Nodality identifi es alterations in intracellular signaling pathways, apoptosis, and DNA repair to monitor drug treatment effects and creates tests to predict which drugs may be effective in specifi c patients. Called single-cell network profi ling (SCNP), the method uses fl ow cytometry to detect changes in cells. In fl ow cytometry, a stream of single cells in fl uid suspension, stained with fl uorescent-labeled antibodies, are illuminated by a laser, which excites the fl uorescence. Some of the fl uorescent light, focused on sensors, generates electrical signals proportional to the number of fl uorescent molecules in each cell. These signals, processed by computer, are plotted onto graphs that depict numbers of cells with the desired properties.
Flow In SCNP, tumor cells are fi xed, made permeable, and stained with fl uorescent antibodies for fl ow cytometry detection of target proteins. But fi rst a special "perturbation" step occurs. The cells are stimulated with some kind of input, such as growth factors, cytokines, or a drug. "The additional trick here is to come at the cell and invoke it with various pokings and proddings to actually stimulate a signaling network to form," explained Nolan at a 2007 lecture, "because it's the signaling network that is informative."
In research studies using SCNP, said Parkinson, as many as 150 different stimuli have been applied to cells before fl ow cytometry. For clinical tests, that number has been reduced to single digits, and antibodies will be used against about a dozen different proteins to profi le activated protumor pathways.
Several 
Western Blotting With a Charge
Another proteomic testing technology with the same goal is the nanofl uidic proteomic immunoassay (NIA). Developed in the laboratory of Dean Felsher, M.D., Ph.D., at Stanford, using instrumentation from Santa Clara, Calif., biotech company Cell Biosciences, NIA has the potential to identify active cellular networks with more sensitivity, and with less tumor material, than SCNP. The test is probably not as close to commercialization, however. Felsher's group reported in Nature Medicine in 2009 that NIA could detect and quantify expression of a variety of proteins in human samples from several tumor types. The technique worked for solid tumor specimens, and monitored cell signaling network changes over time, by using serial biopsies from patients.
NIA traces its lineage to Western blotting, a routine method for detecting protein expression that uses gel electrophoresis to separate proteins by size, using antibodies to identify them on a nitrocellulose sheet. NIA instead takes advantage of the fact that every protein has its own isoelectric point, a pH at which it carries no net electrical charge. Placed along a pH gradient, proteins naturally separate, a process called isoelectric focusing. NIA "really is like a mini -Western blot, except . . . it's isoelectric focusing to separate the proteins, rather than size based," said Alice Fan, M.D., a Stanford lymphoma specialist who led NIA's development in Felsher's lab. Protein separation occurs in tiny fusedsilica capillaries inside a benchtop machine, so that multiple phosphorylated proteins can be identifi ed by using tiny quantities of tumor material ( see illustration). Proteins stick to the inner surface of the capillaries, where antibodies wash over them, followed by a chemiluminescent material. Tiny spots of light mark proteins, which the instrument detects, quantifi es, and interprets. F i n e -n e e d l e a s p i r a t i o n -t h e least invasive form of biopsy -yields more than enough tumor cells, and these don't need to be in suspension. The disadvantage of NIA is that cells must be lysed and analyzed in bulk, as opposed to fl ow cytometry's ability to monitor individual cells. Felsher's group is now working on applying NIA and fl ow cytometry together in some cases.
Stanford is testing NIA in a prospective phase II trial of atorvastatin (Lipitor) to treat indolent lowgrade lymphomas. So far, NIA has revealed that during treatment, phosphorylation of the transcription factors STAT3 and STAT5 decreases in tumor cells from patients, evidence that the drug is altering this pathway. Researchers hope to link these changes to clinical outcome and eventually create a test that will predict which patients will respond to atorvastatin treatment. "At this point, this is exploratory work, and we would need to prove this again prospectively" to validate such a test, said Fan.
One biotech company, Onconova, is already using both SCNP and NIA experimentally. Onconova is completing a phase II trial of its kinase inhibitor, ON 1919.Na, in myelodysplastic syndrome. Researchers take serial bone marrow biopsy samples from patients and run tumor tissue through both tests. "This is very much exploratory, but what we're trying to do is to fi nd some determinants that could predict further response to the drug," said Onconova Chief Medical Offi cer Francois Wilhelm, M.D., Ph.D. At the American Society of Hematology meeting in December, Proteomics in a Pipe: For the nanofl uidic proteomic immunoassay (NIA) diagnostic test, the tumor sample is loaded into a tiny capillary tube. Phosphorylated proteins, separated by isoelectric focusing, stick to the inner surface of the capillary. Washed with antibodies and a luminescent material, they're identifi ed and quantifi ed. This information, researchers hope, will predict individual patient response to drugs. (Image courtesy of Cell Biosciences.)
N E W S
Onconova and Stanford researchers reported that patients who responded to therapy had a 36% decrease in phosphorylation of AKT2, on the basis of NIA analysis. Onconova continues to use NIA and SCNP to identify other changes that could eventually help guide treatment decisions.
Molecular Diagnostics on Trial
Commercializing SCNP and NIA will require rigorous validation, especially in the wake of a scandal at Duke University, which launched three clinical trials using pathway-based gene expression signatures, based on DNA microarrays, to direct cancer patients to different chemotherapy drugs. Researchers at M. D. Anderson, working independently, could not reproduce some of Duke's results linking the signatures to clinical outcomes and found serious methodological errors. The trials were eventually halted, and Duke has retracted some of the fi ndings.
Nodality, Parkinson said, is taking steps to avoid Duke's mistakes. "The Duke example is a real lesson to everyone working in the fi eld about how important it is to do it right," he said. "You have to be extremely careful, because when you're making so many measurements, the possibilities of fi nding a [spurious] positive result are always there." Internally, the company has been careful to ensure data accuracy and reproducibility, using methods and software that meet federal regulatory standards, Parkinson said. Externally, experts from the National Cancer Institute's clinical trial cooperative groups that conducted the original AML trials review the validation study protocols for the diagnostic tests. The company, said Parkinson, is also consulting with the FDA on validation procedures.
Tests such as SCNP and NIA, if they succeed commercially as well as scientifically, will give network profi ling a foothold in the clinical diagnostics world. Newer technologies are already emerging. Nodality is exploring the application of mass spectrometry to a future generation of tests. Other companies are developing network profi ling tests based on microfl uidic "lab on a chip" devices, and various other novel approaches are under development in academic labs worldwide. "Point of care" tests, as opposed to analyzing tumor samples in a central lab, are probably the future. "You can envision [that] you take a sample, load it into the instrument right at the bedside," said Fan. "You can have an answer in 2 hours."
Yet development of all types of molecular tests has been slow. Molecular diagnostics now account for only $3.5 billion of a $40 billion total annual worldwide, in vitro diagnostics market. Success of pathway and network profi ling, in the clinic and in the market, would show that the fi eld is fi nally beginning to realize its potential.
Dr. Fan is coinventor on a Stanford
University patent application for NIA.
